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Exome sequencing was performed in 2 unrelated families
with progressive myoclonus epilepsy. Affected individ-
uals from both families shared a rare, homozygous
c.191A > G variant affecting a splice site in SLC7A6OS.
Analysis of cDNA from lymphoblastoid cells demon-
strated partial splice site abolition and the creation of an
abnormal isoform. Quantitative reverse transcriptase
polymerase chain reaction and Western blot showed a
marked reduction of protein expression. Haplotype anal-
ysis identified a ~0.85cM shared genomic region on
chromosome 16q encompassing the c.191A > G variant,
consistent with a distant ancestor common to both fami-
lies. Our results suggest that biallelic loss-of-function
variants in SLC7A6OS are a novel genetic cause of pro-
gressive myoclonus epilepsy.
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Progressive myoclonus epilepsies (PMEs) are a group ofrare Mendelian disorders defined by the combination
of action and reflex myoclonus, other types of epileptic
seizures, and progressive neurocognitive impairment.1
PMEs usually begin in late childhood or adolescence. Dis-
ease progression is invariable, but prognosis and longevity
vary considerably according to the etiology.
There are >20 known genetic causes of PME.2 They
can be broadly divided into 2 clinical groups. The first
group comprises those associated with significant cognitive
decline, such as Lafora disease. The second group, having
relatively preserved cognition, is largely exemplified by
Unverricht–Lundborg disease (ULD), caused by biallelic
mutations in CSTB.3
Despite recent advances, a substantial proportion of
PME cases remain without a molecular diagnosis, with
more genetic etiologies yet to be discovered.4,5 We report
2 families where multiple relatives are affected with a
“ULD-like” PME phenotype and share the same rare
homozygous splicing variant in SLC7A6OS (solute carrier
family 7 member 6 opposite strand).
Patients and Methods
Ethical Approval and Exome Sequencing
Family 1 (Portuguese origin) was studied in a diagnostic
setting and Family 2 (Turkish origin) in a research setting
(Fig 1A). The institutional review board of Helsinki
University Central Hospital approved the research study.
Following exclusion of dodecamer repeat expansions in
CSTB, paired-end exome sequencing (ES) was performed
on 3 subjects (Family 1: IV-2; Family 2: V-4 and V-6; see
Fig 1A). ES was performed on Nextseq 500 (150bp, Fam-
ily 1) or HiSeq 2000 (75bp, Family 2; Illumina, San
Diego, CA) following standard DNA enrichment proto-
cols and analyzed using appropriate bioinformatic
methods as previously described.6
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FIGURE 1: (A) Family pedigrees showing SLC7A6OS variant segregation and the type of genetic study performed in each
subject. Consanguineous parental unions are indicated with 2 connecting lines. Consanguinity was not reported by the members
of Family 1; however, the families were from the same rural area, and a common ancestor had been hypothesized. Subsequent
inbreeding coefficient calculations supported the consanguineous unions as depicted by the dotted lines. (B) Migration on a
Labchip GX of polymerase chain reaction products obtained by amplification of exons 1 to 3 of blood-derived SLC7A6OS cDNA.
The expected fragment of 455bp was obtained for the 3 individuals tested (Patient III-2 in Family 1, his mother, and a control).
For the patient and his mother, an additional 576bp amplicon was detected, representing, respectively, approximately 20% or
10% of the amount of SLC7A6OS cDNA, with the expected fragment decreasing in proportion. (C) Sanger sequencing of both
the 455 and 576bp amplicons. The “abnormal” transcript corresponds to the retention of the complete intron 1 (+121bp). (D) In
Western blot analysis, a decrease in the abundance of the SLC7A6OS protein was detected in the patient (III-2, Family 1)
compared to controls. The analysis was performed in duplicates with 2 deposits each time. Mean estimations with a ChemiDoc
imager were about 50% of the expression in controls. [Color figure can be viewed at www.annalsofneurology.org]
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Expression Studies in Family 1
Blood-derived RNA samples were collected from the
affected proband (IV-2) and his unaffected mother (III-2).
cDNA was synthesized by standard techniques.7 Primers
specific for “wild-type” SLC7A6OS transcript were used
for real-time polymerase chain reaction (PCR): ex1/2F,
TCCCAGGAGGAACCAGTCCA and ex2R, TCAGGT
TCTCCCTCCTCGTG.
Proteins were extracted from lymphoblastoid cells.
Forty micrograms of each sample was electrophoresed on
NuPAGE 12% Bis-Tris Protein Gels (ThermoFisher Sci-
entific, Waltham, MA) and transferred to Hybond-ECL
Nitrocellulose membrane (GE Healthcare, Velizy-Vil-
lacoublay, France). The membrane was incubated
overnight with primary antibodies: rabbit polyclonal
anti-SLC7A6OS (ab122727; Abcam, Cambridge, UK)
used at dilution of 1:250 or rabbit monoclonal antiactin
antibody SAB5500001, clone SP124, (Sigma-Aldrich,
Saint Louis, MO) used at 1:1,000 in 0.1% phosphate-
buffered saline (PBS)-Tween with 3% milk. After wash-
ing, the membrane was incubated for 1 hour at room tem-
perature with secondary antibodies: donkey antirabbit IgG
H&L (horseradish peroxidase; ab16284) in PBS with 3%
milk. Blots were revealed by ECL Prime kit (Pierce,
Woburn, MA). The chemiluminescent signals of blots
were quantified using a ChemiDoc imager (Bio-Rad,
Marnes-la-Coquette, France).
Post Hoc Linkage and Haplotype Analyses
Nine family members from Family 1 and 6 from Family
2 were single nucleotide polymorphism (SNP) genotyped
(see Fig 1A). Pairwise sample identity-by-descent (IBD)
analyses were performed using KING,8 and inbreeding
coefficients were estimated by FEstim.9 Autosomal reces-
sive linkage analyses were performed using MERLIN.10
Genotyped SNPs were manually interrogated to verify
linkage breakpoints and determine haplotype lengths and
sharing. Copy number variants (CNVs) were detected
using PennCNV.11
Brain Coexpression Exploratory Analysis
Gene coexpression analyses were performed using normal-
ized developing brain expression data from BrainSpan
(http://www.brainspan.org/). Genes were removed if they
had expression values missing from >50% of samples or
expression variation of <0.5 across all samples. A total of
15,957 genes, across 71 samples, remained in the filtered
dataset. Using log2-transformed expression values, a
matrix of weighted pairwise gene correlations was gener-




, where n is the
number of samples contributed by the respective
individual.
Results
Clinical Presentation of Patients
The clinical features of all 6 patients were similar and, in
the early course of disease, resembled classic ULD
(Table ). Electroencephalographic recordings showed rela-
tive preservation of background rhythms with generalized
polyspike, polyspike–wave, and sometimes spike–wave dis-
charges. Discharges were enhanced during hyperventila-
tion and photic stimulation. Giant somatosensory evoked
potentials were documented in patients from both families
(Family 1: IV-2, Family 2: V-1). Brain magnetic reso-
nance imaging at disease onset was normal (Family 1:
IV-2, Family 2: V-6 and V-1), with serial studies in
Family 2 demonstrating deterioration to marked cerebellar
(V-6) and cerebral atrophy (V-1).
Exome Analysis Prioritizes SLC7A6OS Variant
Autosomal recessive modes of inheritance were hypothe-
sized based on pedigree structure (see Fig 1A). Loss-of-
function variants, including predicted splicing variants,
were further prioritized. This approach led to the homozy-
gous SLC7A6OS NM_032178.2: c.191A > G substitution
being identified as the most likely pathogenic variant in
both families (see Supplementary Table S1). Pedigree seg-
regation supported the variant being disease-causing in the
homozygous state (see Fig 1A).
Patient RNA and Protein Expression Studies
The SLC7A6OS c.191A > G affects the second last nucle-
otide of the first exon. Splicing prediction tools predicted
abolition of the donor site (see Supplementary Table S1).
Analysis of cDNA amplicons from exon 1 to exon
3 showed a single expected product of 455bp in controls
(see Fig 1B). In Patient IV-2 and his mother III-2 (Family
1), the normal 455bp product was decreased in amount
and there was an additional product of 576bp (see Fig 1B,
C), resulting from the retention of the intron 1 (121bp),
expected to lead to a frameshift.
Quantification of SLC7A6OS transcripts by quantita-
tive reverse transcriptase polymerase chain reaction in
Patient IV-2 revealed that expression of SLC7A6OS in
blood was approximately 60% and in lymphoblastoid cells
approximately 15% of that in controls. In the blood of the
heterozygous mother (III-2), the SLC7A6OS expression
was approximately 85% of controls. SLC7A6OS protein
expression was also markedly reduced (see Fig 1D).
Post Hoc Linkage and Haplotype Analysis
Inbreeding estimates were consistent with consanguinity
in both families (see Fig 1A). Under an autosomal reces-
sive disease model, a single genome-wide significant link-
age peak (logarithm of odds [LOD] > 3.0) was found for
404 Volume 89, No. 2
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both families on chromosome 16. No other regions with
an LOD score of >0.5 were identified. The homozygous
SLC7A6OS variant is located at chr16:68,344,639bp
(86.6cM); both linkage regions include this base position
(hg19; Fig 2A). No CNVs were detected in the linkage
region for either family.
No close genetic relatedness between the 2 families
was revealed by IBD analysis (third-degree relatives reliably
excluded). However, to explore whether the variant may
have arisen from a distant common ancestor, we compared
the c.191A > G variant haplotype in both families. A total
of 135 consecutive SNPs were shared by the 2 families at
locus chr16q22.1 (chr16: 67,670,682–68,548,709; see Fig
2B). The shared haplotype is ~880kb (~0.85cM) in length,
consistent with a founder effect.
Brain Coexpression Exploratory Analysis
We explored brain coexpression patterns between
SLC7A6OS and genes already known to cause an “ULD-
like” PME phenotype (ie, CSTB, KCNC1, GOSR2,
TABLE. Clinical Presentation and Summary of Affected Individuals from Both Families with the c.191A > G
Variant in SLC7A6OS
Patient ID
Family 1 Family 2
III-3 III-4 IV-2 V-1 V-4 V-6
Sex F M M M F M




Age at onset 21 yr 17 yr 11 yr 12 yrb 13 yr 11 yrc
First symptom TCS TCS Myoclonus TCS Myoclonus TCS
Myoclonus +++ +++ +++ +++ ++ ++
TCS + + + + − +






































































aWalking acquired after the age of 2 years.
bFebrile seizure at 1 year.
cPossible afebrile seizure at the age of 1.5 years and poor balance noted at 9 years.
dSymptom aggravation.
+ = mild; ++ = moderate; +++ = severe; − = not observed; CLB = clobazam; CNZ = clonazepam; DZP = diazepam; F = female; LEV = levetiracetam;
LRZ = lorazepam; M = male; PHT = phenytoin; PRIM = primidone; TCS = tonic-clonic seizures; TPM = topiramate; VPA = valproate; ZNS = zonisamide.
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SCARB2, ASAH1, CERS1).2 The analysis revealed that
SLC7A6OS and SCARB2 are in the top 5% of the most
highly coexpressed genome-wide genes in the developing
brain; SLC7A6OS and GOSR2 are in the top 10%. With
ASAH1, the 4 genes form a set of significantly positively
correlated genes that all negatively correlate with CERS1
(p < 0.01, Monte Carlo sampling).
Discussion
We describe 2 unrelated families with PME and an identi-
cal homozygous variant affecting the splicing of
SLC7A6OS. The similar phenotypic presentation of the
6 patients, combined with a likely founder effect origin of
the variant, strongly suggests that it is the underlying
cause of PME for these patients. Whereas the clinical and
FIGURE 2: (A) Genome-wide parametric linkage logarithm of odds (LOD) scores for Family 1 (dark gray) and Family 2 (light gray)
under an autosomal recessive disease model. (B) Chr16q haplotypes for each family demonstrating the run of homozygosity on
either side of the SLC7A6OS c.191A > G variant in dark gray (Family 1) and light gray (Family 2). The ancestral chr16q22.1
haplotype shared by both families is represented by a small selection of markers from the list of 135 consecutively shared single
nucleotide polymorphisms.
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electrophysiological presentation was similar to ULD,3,12
onset age was slightly later (11–21, mean = 14 years) and
progression with loss of ambulation and cognitive decline
was faster than typical for ULD.
The c.191A > G variant was predicted to disrupt an
SLC7A6OS donor splice site and patient cDNA, and pro-
tein studies confirmed this. We observed the production
of an abnormal isoform with the retention of intron
1. Expression of SLC7A6OS in blood was approximately
60% and in lymphoblastoid cells approximately 15% of
that in controls. Expression of the normal SLC7A6OS
isoform was markedly reduced, which was confirmed by a
decrease of ~50% of the SLC7A6OS protein product.
The exact function of SLC7A6OS remains
unknown, although there is some evidence to support it
playing a role in RNA polymerase II nuclear import.13 In
the zebrafish, slc7a6os is highly expressed in the central
nervous system (CNS) during development.14 Further-
more, functional knockdown of slc7a6os by splice-blocking
morpholinos showed morphological defects in the CNS
and reduced mobility. Interestingly, the morpholino used
by Benini and colleagues14 targets the slc7a6os exon1–
intron1 boundary and is expected to cause the retention
of intron 1 in the mature mRNA, thus mimicking the
effect of the c.191A > G variant in our PME patients.
To further support the role of SLC7A6OS in PME,
we compared its coexpression patterns in the developing
human brain with established “ULD-like” disease genes.
Our analysis identified SCARB2 as the established
“ULD-like” gene, with the most highly correlated brain
coexpression pattern with SLC7A6OS, and that together
with GOSR2, ASAH1, and CERS1 they form a cluster of
significantly coexpressed genes. With a putative role for
SLC7A6OS in nuclear import, all 5 genes are broadly
involved in intracellular trafficking, with correlated
coexpression signatures supporting a potential shared path-
way in the brain specifically.
In conclusion, these data suggest that biallelic
variants in SLC7A6OS, displaying a founder effect, are a
rare, new cause of PME, with a phenotype similar
to ULD.
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